# A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

> **NCT03460977** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 453 (estimated)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Small Cell Lung Cancer (SCLC)
- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** Mervometostat (PF-06821497)
- **DRUG:** Enzalutamide
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT03460977
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-17
- **Primary completion:** 2028-04-20
- **Final completion:** 2029-07-07
- **Target enrollment:** 453 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460977, "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03460977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*